3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects

@article{Vry200432Cyano3trifluoromethylphenoxyphenyl44,
  title={3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects},
  author={J. de Vry and D. Denzer and E. Reissmueller and Maud Eijckenboom and M. Heil and H. Meier and F. Mauler},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2004},
  volume={310},
  pages={620 - 632}
}
  • J. de Vry, D. Denzer, +4 authors F. Mauler
  • Published 2004
  • Chemistry, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
    • 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074) is a novel, selective cannabinoid CB1/CB2 receptor ligand (Ki = 55.4, 48.3, and 45.5 nM at rat and human cannabinoid CB1 and human CB2 receptors, respectively), with partial agonist properties at these receptors in guanosine 5-[γ35S]-thiophosphate triethyl-ammonium salt ([35S]GTPγS) binding assays. In rats, generalization of BAY 59-3074 to the cue induced by the cannabinoid CB1 receptor agonist (–)-(R… CONTINUE READING
    View on ASPET
    jpet.aspetjournals.org
    56 Citations
    Highly Influencial Citations
    4
    Background Citations
    17
    Results Citations
    3

    Paper Mentions

    Interventional Clinical Trial
    Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet
    The purpose of the study is to evaluate whether PG-DN-20WS is a better pain reliever in patients with diabetic neuropathic pain of the feet than a placebo.  
    ConditionsDiabetic Peripheral Neuropathic Pain
    InterventionDrug
    Pure Green
    December 2020 - April 2021
    Interventional Clinical Trial
    The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy
    Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.  
    ConditionsDiabetic Neuropathies
    InterventionDrug
    Pure Green
    September 2019 - June 2020
    56 Citations
    Citation Type

    Citation Type

    Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat.
    • 18
    Attenuation of morphine antinociceptive tolerance by a CB1 receptor agonist and an NMDA receptor antagonist: Interactive effects
    • 22
    • PDF
    Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA
    • 35
    • PDF
    Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: Open-field examination in rats
    • 33
    Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.
    • 11
    Biaryl ether and biaryl analogs as cannabinoid receptor ligands
    • PDF
    (-)-Trans-Δ9-Tetrahydrocannabinol-Like Discriminative-Stimulus Effects of Gabapentin in Cannabis Users.
    • Takato Hiranita
    • Chemistry, Medicine
    • Journal of alcoholism and drug dependence
    • 2016
    • 4
    • PDF
    In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018
    Actions of N-arachidonyl-glycine in a rat neuropathic pain model
    • 65
    Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.
    • 42
    • PDF

    References

    SHOWING 1-10 OF 46 REFERENCES
    Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties.
    • 95
    • PDF
    delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain.
    • 55
    Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist.
    • 12
    Large receptor reserve for cannabinoid actions in the central nervous system.
    • 107
    • PDF
    Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
    • 368
    Intrinsic activity estimation of cannabinoid CB1 receptor ligands in a drug discrimination paradigm
    • 29
    Nociceptin and the ORL‐1 ligand [Phe1ψ (CH2‐NH)Gly2]nociceptin(1‐13)NH2 exert anti‐opioid effects in the Freund's adjuvant‐induced arthritic rat model of chronic pain
    • 58
    The analgesic effects of R(+)-WIN 55,212–2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
    • 286
    CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain
    • 204
    Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats
    • 122